Kaneka (4118) Q3 2025 earnings summary

Executive summary

• Achieved record-high net sales and significant profit growth year-over-year for the April–December 2024 period, with all business segments contributing to increases in both sales and operating income.

• Net sales for the nine months ended December 31, 2024, reached ¥603,048 million, up 6.8% year-over-year, with operating income at ¥29,135 million, up 34.8% year-over-year, and net income attributable to owners of parent at ¥17,736 million, up 32.0% year-over-year.

• All major business segments reported year-over-year increases in both sales and profits, with net sales hitting record highs for both the quarter and the nine-month period.

• Upward revision to full-year forecasts, reflecting continued strong momentum and profitability recovery.

Financial highlights

• Net sales for Apr–Dec 2024: ¥603.0 billion (up 6.8% YoY); operating income: ¥29.1 billion (up 34.8% YoY); net income: ¥17.7 billion (up 32.0% YoY).

• Operating income margin improved to 4.8% from 3.8% YoY.

• Net income per share rose to ¥280.67 from ¥207.04 YoY.

• Total assets as of December 31, 2024, were ¥908,623 million, up from ¥870,205 million at the previous fiscal year-end.

• Net assets rose to ¥484,478 million, with an equity ratio of 51.0%.

Outlook and guidance

• FY2024 full-year forecast: net sales ¥800.0 billion (up 4.9% YoY), operating income ¥40.0 billion (up 22.8% YoY), net income ¥25.0 billion (up 7.7% YoY).

• Upward revision to operating income and net sales guidance.

• Dividend per share increased from initial plan of ¥120 to ¥130; progressive dividend policy planned for FY2025–2027.

• All major business segments are expected to maintain or improve performance in 4Q, with particular strength anticipated in Medical, Pharma, and Nutrition.